How to Assess a Small Molecule HPAPI CDMO in 2026

What Defines a High-Potency Active Pharmaceutical Ingredient Programme?

A contract development and manufacturing organisation is ready for a high-potency active pharmaceutical ingredient programme when it can demonstrate validated occupational exposure classification, specialist formulation infrastructure, trace-level analytical capability, risk-based technology transfer protocols, current Good Manufacturing Practice certification and genuine integration across the development-to-supply pathway.

A high-potency active pharmaceutical ingredient is generally defined as a compound with a pharmacological effect or toxicological concern at very low doses, typically requiring an occupational exposure limit below 10 micrograms per cubic metre of air. These compounds include, but are not limited to, cytotoxic agents, highly selective hormone analogues and certain oncology small molecules.

From a development perspective, high-potency active pharmaceutical ingredient programmes demand specialist knowledge across three intersecting disciplines: containment engineering, formulation science and analytical chemistry. No single capability can be assessed in isolation. A contract development and manufacturing organisation that demonstrates strong containment but lacks the formulation depth to bring a potent small molecule to a regulatory-ready state introduces a different category of risk.

The Six Criteria for Assessing a Small Molecule HPAPI CDMO

1. Occupational Exposure Classification and Containment Strategy

Before formulation work begins, a competent contract development and manufacturing organisation must demonstrate a structured approach to occupational exposure banding. This process assigns a compound to an occupational exposure band based on its pharmacological activity, toxicological profile and available safety data. That classification directly determines the engineering controls required during handling, weighing, formulation and cleaning.

Key questions to ask a prospective partner include:

• Does the organisation operate a formal hazard assessment protocol for new high-potency active pharmaceutical ingredient programmes?
• Are containment systems validated and documented to meet the assigned occupational exposure band?
• What is the process for handling compounds with incomplete safety data or early-stage toxicological profiles?
• Are contained equipment cleaning procedures validated and qualified?

A contract development and manufacturing organisation that cannot clearly articulate its occupational exposure classification workflow should not be considered for high-potency active pharmaceutical ingredient development. The quality of that process directly affects personnel safety, facility contamination risk and the integrity of your compound throughout the development cycle.

2. Small Molecule Formulation Expertise

High-potency active pharmaceutical ingredients present particular formulation challenges. Their extreme pharmacological potency at low doses means that the uniformity of content across a batch is a critical quality attribute. For solid oral dosage forms, achieving acceptable content uniformity at very low drug loading requires specialist blending, granulation and processing knowledge. For sterile dosage forms, solubility limitations common to many potent small molecules demand advanced formulation strategies.

Assess the contract development and manufacturing organisation’s formulation capability against the following:

• Demonstrated experience developing dosage forms relevant to your target product profile, including tablets, sterile vials and injectable presentations
• Laboratory capacity for early-stage feasibility and pilot batch work at sub-gram and gram scale
• Expertise in dosage form optimisation, including solubility enhancement and drug release profiling
• A documented approach to formulation risk assessment prior to Good Manufacturing Practice manufacture
• Confirmed capability across all relevant dosage forms, from solid oral dose through to sterile presentations

Breadth of dosage form experience matters. A contract development and manufacturing organisation that covers development across all relevant dosage forms can support the programme as clinical and commercial requirements evolve, without requiring a change of partner at a later and higher-risk stage.

3. Analytical Development and Method Validation

For high-potency active pharmaceutical ingredient programmes, analytical capability is not a supporting activity; it is a foundational requirement. The detection and quantification of a potent compound at very low concentrations demands validated methods that are both sensitive and selective. Regulatory agencies expect these methods to be developed, transferred and validated in accordance with International Council for Harmonisation guidelines, and the contract development and manufacturing organisation must be able to demonstrate this rigorously.

Critical analytical considerations include:

• High-performance liquid chromatography method development and validation for content uniformity and release testing
• Cleaning validation methods capable of detecting residues at trace levels
• Stability testing capacity aligned to International Council for Harmonisation conditions, supporting both development and regulatory submissions
• Sterility and endotoxin testing capability for injectable presentations
• Bioburden assessment for non-sterile development activities

Method transfer capability is equally important. If the contract development and manufacturing organisation holds the methods but cannot transfer them cleanly to your analytical testing site or to a commercial partner, the programme carries unnecessary risk at scale-up. Confirm that the organisation has a documented method transfer process with clear acceptance criteria before any agreement is signed.

4. Technology Transfer and Scale-Up Readiness

Technology transfer from development to clinical manufacturing, and subsequently from clinical to commercial scale, is consistently one of the highest-risk transitions in pharmaceutical development. For high-potency active pharmaceutical ingredient programmes, the complexity increases. Containment systems, cleaning procedures and in-process controls must all be re-qualified at each scale, and the contract development and manufacturing organisation must have the process development infrastructure to anticipate where failures are likely to occur.

Evaluate the organisation’s technology transfer capability by examining:

• The robustness of its technology transfer protocols and whether they include formal risk assessment
• Experience transferring both inward and outward programmes across high-potency active pharmaceutical ingredient dosage forms
• The availability of development-scale equipment that mirrors the geometry and operating principles of Good Manufacturing Practice manufacturing equipment
• Documented scale-up experience, including batch records and deviation histories that demonstrate how process challenges were resolved

A contract development and manufacturing organisation that treats technology transfer as a project management exercise rather than a scientific and risk-based process is likely to encounter avoidable failures during scale-up that carry direct regulatory and timeline consequences.

5. Regulatory and Good Manufacturing Practice Compliance

For high-potency active pharmaceutical ingredient programmes, Good Manufacturing Practice compliance and regulatory readiness carry additional weight because regulatory authorities scrutinise containment and occupational health controls as part of their facility inspections. A contract development and manufacturing organisation operating under EU-GMP certification and with demonstrated compliance with United States Food and Drug Administration regulations provides the broadest market access and the strongest evidence of operational discipline.

Specific regulatory considerations to confirm:

• Current Good Manufacturing Practice certification status and the scope of the certificate relative to your programme
• History of regulatory inspections, including the number of inspections and the nature of any observations
• Capability to support regulatory submissions, including dossier preparation, Chemistry Manufacturing and Controls sections and responses to agency questions
• Experience supporting submissions across multiple geographies, particularly where your commercial strategy requires approvals in the European Union, the United States and other regulated markets

Regulatory experience is not limited to manufacturing. A contract development and manufacturing organisation with a track record of successfully supporting electronic Common Technical Document dossier submissions and product approvals across multiple markets brings a material advantage during the clinical and registration phases.

6. Integration Across the Development-to-Supply Pathway

The final and frequently underweighted criterion is integration. Many development organisations select a contract development and manufacturing organisation for a single phase of their programme only to encounter significant friction when transitioning to the next. For high-potency active pharmaceutical ingredient programmes, these transitions carry elevated risk. Selecting a partner with genuine end-to-end capability, from early feasibility and preclinical material supply through to Good Manufacturing Practice clinical batch production and commercial scale manufacturing, substantially reduces that risk.

Consider the following questions when assessing integration:

• Does the contract development and manufacturing organisation offer drug development services that are genuinely connected to its Good Manufacturing Practice manufacturing capabilities, rather than operating as separate business units?
• Can the organisation manage clinical trial materials, including secondary packaging, clinical kit preparation and temperature-controlled distribution?
• Is there a single point of contact who provides continuity from development through to batch release?
• Does the contract development and manufacturing organisation have a proactive regulatory strategy function that supports dossier development alongside the manufacturing programme?

An integrated partner is one who has invested in the success of your programme beyond the boundaries of a single contract. That orientation changes the nature of the relationship and the quality of decisions made throughout the programme lifecycle.

Questions to Ask During CDMO Due Diligence

The following questions are appropriate to pose during an initial capability assessment or site qualification visit for a high-potency active pharmaceutical ingredient programme:

• What occupational exposure bands does your facility currently handle, and what documentation supports that classification?
• Describe a recent high-potency active pharmaceutical ingredient technology transfer you managed. What challenges did you encounter and how were they resolved?
• How do you approach formulation feasibility for a new molecule with limited safety data?
• What is your process for developing and validating cleaning procedures for high-potency compounds?
• How many electronic Common Technical Document dossier submissions have your development teams supported, and in which jurisdictions?
• How is your quality system structured to handle deviations during high-potency active pharmaceutical ingredient manufacturing?
• What is the minimum dataset you require before initiating formulation feasibility work on a new high-potency compound?

Clear, specific and well-documented answers to these questions provide a meaningful signal of a contract development and manufacturing organisation’s actual capability, rather than its marketed positioning.

How Adragos Pharma Addresses HPAPI Development Needs

Adragos Pharma operates as a global contract development and manufacturing organisation with Good Manufacturing Practice facilities across Switzerland, Germany, France, Greece, Norway and Japan. For small molecule high-potency active pharmaceutical ingredient programmes specifically, the Athens, Greece site functions as the dedicated development hub within the Adragos network.

Athens, Greece: The Dedicated HPAPI Development Centre

The Athens facility serves as Adragos’ centre of excellence for pharmaceutical research and development, with a specific focus on small molecule development, new chemical entities and value-added medicines. The site has recently been upgraded with high-potency active pharmaceutical ingredient handling capabilities and includes more than 70 professionals engaged in pharmaceutical research and development.

The Athens team has supported over 150 electronic Common Technical Document dossier submissions and achieved product approvals in more than 20 countries. The site holds expertise across all dosage forms, handles both high-potency active pharmaceutical ingredients and controlled substances, and operates under EU-GMP certification with compliance with United States Food and Drug Administration regulations. For development leaders seeking a single site that combines formulation science, analytical capability, regulatory knowledge and dedicated high-potency active pharmaceutical ingredient infrastructure, Athens represents an integrated starting point for any potent small molecule programme.

Adragos Jura, Switzerland: Sterile Clinical and Commercial Manufacturing

For programmes that have completed formulation and analytical development and require aseptic fill-and-finish for liquid and lyophilised vials, the Adragos Jura site in Switzerland provides a dedicated sterile manufacturing capability for small molecules and biological products. Jura operates with no minimum batch size and produces up to 74,000 vials per batch, with a three-month response time from order to a Good Manufacturing Practice batch including controlled drug handling.

The Jura site produces approximately 200 clinical batches per year and has supported five successful commercial launches. It is certified by the European Medicines Agency, the United States Food and Drug Administration and Swissmedic. For development teams who require a reliable, audit-ready sterile manufacturing partner for clinical supply following development, Jura provides both the technical capacity and the regulatory standing to support global submissions within the same contract development and manufacturing organisation relationship.

A Network Built for Programme Continuity

Across the Adragos network, the organisation draws on what it describes as three centuries of collective experience from leading pharmaceutical, biotechnology and strategy organisations. The research and development model is directly oriented towards regulatory-ready, scalable and market-relevant output, with a stated commitment to investing in each asset’s success beyond standard project timelines. For development leaders, the combination of a dedicated high-potency active pharmaceutical ingredient development site in Athens and a Good Manufacturing Practice-certified sterile manufacturing facility in Jura means that a small molecule programme can progress from early feasibility to clinical supply within a single partner relationship.

Summary: What to Look for in an HPAPI CDMO

To assess a contract development and manufacturing organisation for a small molecule high-potency active pharmaceutical ingredient programme, evaluate the following six areas in this order:

Assessment Area	Key Criteria
Occupational Exposure Classification and Containment	Formal hazard banding, validated containment systems and qualified cleaning procedures
Formulation Expertise	Breadth of dosage form capability, early-stage feasibility capacity and documented content uniformity experience
Analytical Development	Validated methods at trace-level sensitivity, International Council for Harmonisation-compliant stability programmes and method transfer protocols
Technology Transfer	Risk-based transfer protocols, scale-appropriate development equipment and documented scale-up experience
Regulatory and Good Manufacturing Practice Compliance	Current certification scope, inspection history and electronic Common Technical Document dossier submission track record
Programme Integration	Continuity from development through to commercial supply and a single-point-of-contact model

A contract development and manufacturing organisation that performs strongly across all six areas is positioned to carry a high-potency active pharmaceutical ingredient programme from early feasibility to regulatory submission without the operational discontinuities that cost time and quality.

Frequently Asked Questions

What is a high-potency active pharmaceutical ingredient?

A high-potency active pharmaceutical ingredient is a compound with significant pharmacological activity or toxicological concern at very low doses. These compounds typically require an occupational exposure limit below 10 micrograms per cubic metre of air and demand specialist containment, handling and formulation controls throughout development and manufacturing. Common examples include cytotoxic oncology compounds, potent hormone analogues and certain targeted small molecules in development for rare diseases.

What occupational exposure banding systems do CDMOs use for HPAPI classification?

Contract development and manufacturing organisations typically use occupational exposure banding systems that group compounds into bands based on pharmacological potency, toxicological data, physical and chemical properties and available human safety data. Each band corresponds to a defined range of acceptable occupational exposure limits and prescribes the engineering controls required during handling. A well-qualified contract development and manufacturing organisation will have a documented classification protocol and will be able to apply it to compounds with incomplete safety data, which is common in early-phase development.

Why is content uniformity a critical quality attribute for HPAPI small molecule formulations?

For high-potency active pharmaceutical ingredients, the therapeutic dose is typically very small in absolute terms, meaning the active compound is present in the dosage form at very low drug loading. At low drug loading, minor variations in the distribution of the active compound across a batch can result in individual doses that are meaningfully above or below the intended dose. Given the steep dose-response relationship of many potent compounds, this creates a direct patient safety concern. Regulatory agencies require content uniformity to be demonstrated across the batch, and achieving this demands specialist formulation techniques including controlled blending, precision granulation and validated in-process sampling.

What regulatory certifications should a CDMO hold for HPAPI development programmes?

As a minimum, a contract development and manufacturing organisation handling high-potency active pharmaceutical ingredients should hold a current Good Manufacturing Practice certificate covering the scope of activities relevant to your programme. For European market access, EU-GMP certification is required. For programmes targeting the United States, compliance with United States Food and Drug Administration current Good Manufacturing Practice regulations must be demonstrated. Regulatory authorities also scrutinise containment infrastructure and occupational health controls during inspections of high-potency active pharmaceutical ingredient facilities, so a site’s inspection history is an important data point alongside its certification status.

What is the difference between HPAPI development and HPAPI manufacturing?

High-potency active pharmaceutical ingredient development covers the scientific activities required to establish a viable, regulatory-ready dosage form: formulation feasibility, analytical method development and validation, stability studies and process development. High-potency active pharmaceutical ingredient manufacturing refers to the Good Manufacturing Practice-compliant production of batches for clinical or commercial supply under validated conditions. Many contract development and manufacturing organisations offer one or the other. An integrated partner that offers both reduces the risk of knowledge loss, documentation gaps and timeline delays that arise when transferring between separate development and manufacturing providers.

How does Adragos Pharma support small molecule HPAPI programmes?

The Adragos Athens facility in Greece serves as the dedicated centre of excellence for high-potency active pharmaceutical ingredient development within the Adragos network. The site has recently been upgraded with high-potency active pharmaceutical ingredient handling capabilities and includes more than 70 professionals engaged in pharmaceutical research and development. Athens covers formulation development across all dosage forms, handles controlled substances, holds EU-GMP certification and operates in compliance with United States Food and Drug Administration regulations. The team has supported over 150 electronic Common Technical Document dossier submissions with product approvals in more than 20 countries. For programmes that subsequently require sterile clinical or commercial manufacturing, the Adragos Jura site in Switzerland provides aseptic fill-and-finish for liquid and lyophilised vials, certified by the European Medicines Agency, the United States Food and Drug Administration and Swissmedic.

How long does HPAPI small molecule formulation development typically take at a CDMO?

The timeline for high-potency active pharmaceutical ingredient small molecule formulation development depends on the complexity of the molecule, the depth of existing physicochemical and safety data, the target dosage form and the regulatory requirements of the intended submission. Formulation feasibility studies for a well-characterised molecule may take a matter of months, while programmes involving novel compounds with limited data, complex solubility profiles or multiple dosage form options will require longer development phases. It is not appropriate to specify timelines without reference to a specific molecule and programme. Discuss your compound profile directly with a development team to receive a realistic and evidence-based programme estimate.